Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback